성병 분자진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 지역별, 부문 예측(2025-2033년)

Molecular Diagnostics For STD Market Summary

The global molecular diagnostics for sexually transmitted diseases (STDs) market size was estimated at USD 3.36 billion in 2024 and is projected to reach USD 6.94 billion by 2030, growing at a CAGR of 8.35% from 2025 to 2033. The increasing incidence of sexually transmitted infections such as chlamydia, gonorrhea, syphilis, and human papillomavirus (HPV) is a key factor driving market growth.

The demand for accurate and early detection contributes to the uptake of molecular diagnostic tools. Improvements in nucleic acid amplification technologies and growing awareness about regular STD screening are also supporting market expansion. Supporting this trend, diagnostic developers are concentrating on next-generation molecular tests that offer rapid, multiplexed, and high-throughput detection of sexually transmitted pathogens. Recent innovations include point-of-care nucleic acid amplification tests and portable PCR-based devices designed to deliver accurate results in minimal time. For instance, in March 2025, Visby Medical received U.S. Food and Drug Administration (FDA) De Novo authorization for its Women's Sexual Health Test, the first over-the-counter PCR diagnostic device approved for at-home use. This palm-sized device enables rapid, reliable testing for chlamydia, gonorrhea, and trichomoniasis, providing results within 30 minutes without needing laboratory processing. Such advancements reflect the market's focus on expanding access to reliable testing, reducing diagnostic turnaround time, and enhancing patient management through early and precise detection.

Moreover, technological progress in molecular diagnostic research has enabled the development of more sensitive, specific, and targeted tests for sexually transmitted infections. Innovations in assay design, sample processing, and amplification techniques have improved diagnostic accuracy and reduced false negatives, crucial for effective disease management. These advancements help address existing challenges in detecting asymptomatic infections and co-infections, especially in high-risk populations. In addition, continued investment in research by diagnostic manufacturers and public health organizations supports the expansion of molecular diagnostics pipelines and promotes wider availability across diverse healthcare settings.

Despite ongoing progress, the molecular diagnostics for STD market faces several challenges that may limit growth. The development, validation, and regulatory approval of new molecular tests require substantial time and resources, with manufacturers needing to comply with rigorous safety and performance standards. These factors often cause delays in product launches and restrict market availability. In addition, ensuring consistent access to diagnostic technologies presents logistical difficulties, especially in regions with limited healthcare infrastructure. The need for reliable sample storage, transportation, and skilled personnel complicates test deployment in remote or underserved areas. These challenges highlight the necessity for coordinated efforts to address regulatory hurdles and improve distribution networks to expand access to molecular diagnostics for STDs worldwide.

Global Molecular Diagnostics For STDs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics for sexually transmitted diseases (STDs) market report based on product, application, technology, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments & Services
• Consumables (Reagents and kits)
• Softwares
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• CT/NG Testing
• Syphilis Testing
• Gonorrhea Testing
• HSV Testing
• HPV Testing
• HIV Testing
• Trichomonas
• Ureaplasma + Mycoplasma
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Testing
  • Commercial/Private Labs
  • Public Health Labs
• PoC testing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Movement Analysis, 2024 & 2033 (USD Million)
• 4.3. Instruments & Services
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Consumables (Reagents and kits)
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Software
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Movement Analysis, 2024 & 2033 (USD Million)
• 5.3. CT/NG testing
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Syphilis testing
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Gonorrhea testing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. HSV testing
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. HPV testing
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. HIV testing
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Trichomonas
  • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Ureaplasma + Mycoplasma
  • 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Movement Analysis, 2024 & 2033 (USD Million)
• 6.3. Laboratory Testing
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Commercial/Private Labs
    • 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Public Health Labs
    • 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. PoC testing
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

• 7.1. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Share, By Region, 2024 & 2033, USD Million
• 7.2. North America
  • 7.2.1. North America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. China Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Australia Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. South Korea
    • 7.4.6.1. South Korea Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. BD
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. F. Hoffmann-La Roche Ltd
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Hologic Inc.
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Abbott
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Cepheid (Danaher)
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Qiagen
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. OraSure Technologies, Inc.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Bio-Rad Laboratories, Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. bioMerieux SA
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Thermo Fisher Scientific, Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives
  • 8.4.11. Seegene Inc.
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/ Strategic Initiatives
  • 8.4.12. DiaSorin S.p.A
    • 8.4.12.1. Participant's Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Recent Developments/ Strategic Initiatives